Supplemental Figure 6
Wild-type C57BL/6 mice that had rejected B16.BRAFIR melanomas after systemic PLX-4720
and anti-integrin-αv mAb treatment showed specific long-term protection against subsequent challenge with B16 melanomas (B16: rechallenge), but not unrelated MC38 colon carcinomas (MC38: rechallenge) during the follow-up period (> 60 days). The untreated B16 tumors in naïve C57BL/6 mice were used as a control (NT). Each experiment was performed with four mice per group, and similar results were observed in three independent experiments.
Supplemental Figure 7
C57BL/6 mice harboring established B16.V600E melanomas (25 mm 2 ) were treated with systemic PLX-4720 and anti-integrin-αv mAb (RMV-7). Tumor-draining lymph node (TDL)
were harvested 5 d after the treatment, and CD3 + CD4 + gated cells were assayed for FoxP3 and
IFNγ by flow cytometry (percentages of the upper-right gradient are shown).
Supplemental Figure 8
Integrin-αvβ3 regulates ingestion of viable tumor cells by DCs. 
